1. Acute tumor lysis syndrome in solid tumors—a case report and review of the literature

   • L. Baeksgaard
   • J. B. Sørensen

   Review 28 February 2003 Pages: 187 - 192

   

2. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome

   • Jon C. Mirsalis
   • Janice Schindler-Horvat
   • Susan J. Donohue

   Original Article 18 January 2003 Pages: 193 - 201

   

3. Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells

   • Takefumi Komiya
   • Nobuhiro Fusetani
   • Kazuhiko Nakagawa

   Original Article 14 January 2003 Pages: 202 - 208

   

4. Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH₃, is mediated by inhibition of cytokinesis

   • Hye-Kyung Na
   • Chia-Cheng Chang
   • James E. Trosko

   Original Article 28 February 2003 Pages: 209 - 215

   

5. Stimulation of intestinal epithelial restitution by prostaglandin E₁ analogue

   • Kohji Hirata
   • Toshiharu Horie

   Original Article 26 February 2003 Pages: 216 - 220

   

6. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies

   • Bea Pauwels
   • Annelies E. C. Korst
   • Jan B. Vermorken

   Original Article 22 January 2003 Pages: 221 - 226

   

7. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors

   • Nithya Ramnath
   • Gary N. Schwartz
   • Patrick J. Creaven

   Original Article 25 February 2003 Pages: 227 - 230

   

8. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine

   • A. Aparicio
   • C. A. Eads
   • J. S. Weber

   Original Article 27 February 2003 Pages: 231 - 239

   

9. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1–5 for gastric cancer, and its pharmacologic and kinetic rationale

   • Masanori Terashima
   • Takashi Irinoda
   • Tetsuhiko Shirasaka

   Original Article 11 February 2003 Pages: 240 - 246

   

10. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts

    • Ningping Feng
    • Hongnan Jin
    • Aiping H. Young

    Original Article 05 March 2003 Pages: 247 - 255

    

11. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia

    • Akitoshi Kinoshita
    • Yoshihiro Kurosawa
    • Shinpei Nakazawa

    Original Article 17 January 2003 Pages: 256 - 260

    

12. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT

    • Sebastian Bauer
    • Christopher L. Corless
    • Jochen Schütte

    Clinical Trial Report 26 February 2003 Pages: 261 - 265

    

13. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment

    • Alexander Kiani
    • Claus-Henning Köhne
    • Eberhard Schleyer

    Clinical Trial Report 04 March 2003 Pages: 266 - 270